Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

LONDON, May 16 (Reuters) - Wegovy-maker Novo Nordisk (NOVOb.CO), opens new tab said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

Jorgensen, who after eight years in the role is one of the shortest-serving CEOs at Novo Nordisk, told Reuters on Friday that he has not met with Trump but has met with Trump administration officials.